9 results about "Irritable colon" patented technology

The present application relates to the technical field of medical information analysis, in particular to a IBS-D symptom dynamic monitoring and doctor-patient interaction terminal, the present application extracts first characteristic medical information and second characteristic medical information through an irritable bowel feedback analysis model, and the second characteristic medical information is calibrated and quantified to obtain third characteristic medical information under the condition of containing the first characteristic medical information; the first characteristic medical information and the third characteristic medical information are combined as key quantitative information to generate an IBS-D medical monitoring feature report; through the method, the physiological information and the communication information of the monitored IBS-D patient can be quantified, and a medical monitoring feature report is generated based on the information, so as to expand the application range of the monitoring data to the treatment data, reduce the communication information error caused by the disease of the patient, and provide accurate data for the doctor to make data reference.

The present disclosure encompasses compositions prepared from kiwifruit. In particular, the invention encompasses compositions prepared from gold varieties of Actinidia chinensis. Also encompassed are methods of preparing these compositions. Further encompassed are methods of using these compositions, in particular, for treating or preventing disorders of the gastrointestinal system, including amongst others: inflammation, constipation, bowel irregularity, microbiota imbalances, irritable bowel syndrome, and inflammatory bowel disease.

The invention relates to a traditional Chinese medicine composition for treating irritable bowel syndrome and a preparation method thereof. The composition comprises a white peony root active component purified by macroporous resin, a pasty dried orange peel extract, a pasty licorice extract, an adhesive and the like, and also can be further added with bighead atractylodes rhizome, divaricate saposhnikovia root, fructus amomi and other components. The preparation method comprises the steps of white peony root powder preparation, ultrasonic extraction, macroporous resin purification, concentration and drying, auxiliary component preparation, mixing and granulation and the like. The purity of active ingredients of the radix paeoniae alba is improved through a purification process, the treatment effect on the irritable bowel syndrome is enhanced through the synergistic effect of all the ingredients, and the prepared granules are more stable in treatment effect on the irritable bowel syndrome and suitable for various people.

This invention discloses the application of porcine bile acid components in the preparation of drugs for treating irritable bowel syndrome (IBS-D). The study found that the content of porcine bile acid components in the peripheral feces of IBS-D patients treated with traditional Chinese medicine was significantly increased. Furthermore, compared with a healthy control group, the content of porcine bile acid components in the peripheral fecal samples of IBS-D patients was significantly reduced. Further research revealed that porcine deoxycholic acid and natural traditional Chinese medicine porcine bile powder can significantly improve diarrhea and abdominal pain symptoms in TNBS-induced mice by inhibiting tryptophan hydroxylase 1 activity and reducing peripheral serotonin levels. This invention suggests the application value of porcine bile acid components in the treatment of IBS-D.

Provided herein are methods for detecting inflammatory bowel disease (IBD) or risk of IBD in a canine based on the canine's gut microbiome. Also provided are methods for treating or preventing IBD in canines. Finally provided are probiotic compositions that are used in the methods of the present disclosure.

The invention relates to the technical field of medicines, discovers that a natural product glabroolide can be used as an M3 (M3) receptor stimulant and application thereof, and particularly relates to discovery of a glabroolide action target spot, the target spot is an M3 receptor, the M3 receptor stimulant is glabroolide or a derivative thereof, and the application of the glabroolide in the M3 receptor stimulant is shown in the description. And one or more than two of the corresponding pharmaceutically acceptable salts of the compound are active ingredients, and in-vitro cell experiments show that the compound is an M3 receptor agonist. At present, researches show that the M3 receptor is related to heart diseases, respiratory diseases, sicca syndrome, peptic ulcer disease, frequent urination, prune syndrome, chronic obstructive pulmonary disease, cirrhosis, irritable bowel syndrome and other diseases, while the M3 receptor stimulant has a protective effect on myocardial cell injury. The compound has a certain treatment effect on diseases such as arrhythmia, respiratory depression and sicca syndrome, so that a novel M3 receptor agonist Miao compound with a clear action target can be provided for the related diseases.

A series of 8-phenyl-isoquinoline derivatives (I) exhibit high binding affinity for the 5-HT7 receptor (5HT7R) and show potential analgesic activity in two animal models of irritable bowel syndrome (IBS) by intraperitoneal injection (i.p.) or by oral gavage (p.o.). These 5-HT7 receptor antagonists are a novel class of therapeutic agents for the treatment of IBS. #imgabs0#

The invention relates to the technical field of medical information analysis, in particular to an IBS-D symptom dynamic monitoring and doctor-patient interaction terminal, which is characterized in that first feature medical information and second feature medical information are extracted through an irritable bowel feedback analysis model; performing data quantification calibration on the second feature medical information under the condition that the first feature medical information is included to obtain third feature medical information; combining the first feature medical information and the third feature medical information as key quantitative information to generate an IBS-D medical monitoring feature report; through the method, data quantification can be performed on monitored physiological information and communication information of IBS-D patients, and a medical monitoring feature report is generated based on the information, so that the application range of monitoring data to treatment data is expanded, communication information errors caused by diseases of the patients are reduced, and accurate data are provided for doctors for data reference.

Provided herein are methods for detecting inflammatory bowel disease (IBD) or risk of IBD in a canine based on the canine's gut microbiome. Also provided are methods for treating or preventing IBD in canines. Finally provided are probiotic compositions that are used in the methods of the present disclosure.